UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPI	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person *- GOLDBERG DAVID C				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Director Director				
(Last) (First) (Middle) C/O ENZO BIOCHEM INC., 527 MADISON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 01/17/2013						X_0	X Officer (give title below) Other (specify below) VP CorpDev IGM Enz Clin Labs				
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group FilingCheck Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
NEW YO	ORK, NY	(State)	(Zip)													
(CI	.y)	(State)	(Zip)	<u> </u>			Tab	ole I - Non-D	erivat	ive Securities	Acquired, D	oisposed o	f, or Benefi	cially Owned		
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	2A. Deem Execution any (Month/D			Coc	ransaction le str. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(D) Owned			. (Ownership	7. Nature of Indirect Beneficial	
					Day/Year)		Code V	Amo	(A) or unt (D) F	(Instr.	(Instr. 3 and 4)		or (I)	Indirect (1	Ownership Instr. 4)	
Damindar	Papart on a	congrata lina for again	class of securities b	anafiaia	llv o	wand dire	<u> </u>			(<i>D</i>) [1	1100					
Reminder.	Report on a s	separate fine for each	relass of securities t	enericia	ny o	wheat and	cuy	Perso	ons w s forn	ho respond to n are not required valid OMB o	uired to res	spond ur				474 (9-02)
			Table I							of, or Benefic		l				
(Instr. 3) Price Deriv				4. Transac Code	4. Transaction Code (Instr. 8)		er	6. Date Exercise Expiration Date (Month/Day/Ye		le and	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivative Security: Direct (D or Indirect	Beneficial Ownershij (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option		01/17/2013		A		27,429		01/17/201	14(1)	01/17/2018	Common Stock	27,429	\$ 0	27,429	D	

D (1 0 N /	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GOLDBERG DAVID C C/O ENZO BIOCHEM INC. 527 MADISON AVENUE NEW YORK, NY 10022			VP CorpDev IGM Enz Clin Labs				

Signatures

/s/ David C. Goldberg	01/22/2013
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Reporting Person was granted 27,429 Stock Options. The Options have a five year term which shall vest in three equal installments, commencing on January 17, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.